Gene therapy rising: Bluebird soars at ASH, Pfizer builds platform
This article was originally published in Scrip
Executive Summary
With the potential to cure debilitating diseases, gene therapy has become a darling of the biotechnology industry. The latest evidence: Bluebird Bio's 8 December after-hours stock market rise by 43.2% to $70 per share on data from four transfusion-free beta-thalassemia patients and Pfizer's investment in a gene therapy platform that includes a hemophilia B collaboration with Spark Therapeutics.
You may also be interested in...
BioMarin, Spark Hemophilia Gene Therapies Progress As Accelerated Approval Favors Their Indications
As updated Phase I/II results for BioMarin's hemophilia A and Spark's hemophilia B gene therapies were presented on May 22, it was revealed that FDA plans to make hemophilia the first gene therapy indication eligible for accelerated approval based on a surrogate endpoint.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.